Metagenomi Therapeutics earnings were -$85.9M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest MGX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$23.1M, up 2.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MGX reported annual earnings of -$87.9M, with 12.6% growth.
Metagenomi Therapeutics Earnings Reports & History FAQ
What were Metagenomi Therapeutics's earnings last quarter?
On MGX's earnings call on Invalid Date, Metagenomi Therapeutics (NASDAQ: MGX) reported Q1 2026 earnings per share (EPS) of -$0.61, up 10.29% year over year. Total MGX earnings for the quarter were -$23.06 million. In the same quarter last year, Metagenomi Therapeutics's earnings per share (EPS) was -$0.68.
Is Metagenomi Therapeutics profitable or losing money?
As of the last Metagenomi Therapeutics earnings report, Metagenomi Therapeutics is currently losing money. Metagenomi Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$85.89 million, a 10.18% increase year over year.
What was MGX's earnings growth in the past year?
As of Metagenomi Therapeutics's earnings date in Invalid Date, Metagenomi Therapeutics's earnings has grown year over year. MGX earnings in the past year totalled -$85.89 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.